Uterine fibroids (myomas) in Mêda, Portugal: diagnosis, treatment and reference centres
Editorial guide to Uterine fibroids (myomas) in Mêda (Guarda, Portugal). Diagnostic criteria, evidence-based treatment options, authorised centres, and official sources. ESHRE Position Paper on Uterine Fibroids and Reproduction.
Uterine fibroids (myomas) is a recognised medical condition affecting fertility and requiring specialist evaluation. Benign tumours of the myometrium. Location and size affect fertility and implantation rates. This page presents, for patients in Mêda (Guarda district, Centro region), the recommended clinical pathway, evidence-based treatment options, and where to access care in Portugal. All information is verified against ESHRE Position Paper on Uterine Fibroids and Reproduction and reviewed by our editorial team — see our methodology.
Prevalence and impact
Around 70% of women develop fibroids by age 50; ~25% symptomatic. In infertility patients, prevalence is ~5–10%.
Portugal does not publish population-level epidemiological registries specific to Uterine fibroids (myomas), but international data applies. Regionally, demand for reproductive medicine consultations in Centro has risen steadily since 2010 per CNPMA annual reports. This reflects both delayed motherhood (mean age at first child in Portugal: 31.2 years, INE 2024) and greater reproductive health literacy.
Early recognition of Uterine fibroids (myomas) preserves treatment options. Women with risk factors — family history, irregular cycles, chronic pelvic pain, or unsuccessful conception attempts ≥6 months at age >35 — should seek specialist evaluation without waiting the conventional 12 months.
How Uterine fibroids (myomas) is diagnosed
Transvaginal ultrasound (first line). Saline infusion sonography or hysteroscopy for submucosal fibroids. Pelvic MRI for pre-surgical mapping of multi-fibroid uteri. FIGO classification 0–8 (submucosal 0–2 → intramural → subserosal).
In Portuguese practice, the pathway is: (1) GP consultation for baseline labs and ultrasound; (2) referral to gynaecology / reproductive medicine via SNS or direct private consultation; (3) full couple work-up even when the symptom seems isolated to one partner. In Mêda, the couple is typically referred to Guarda or another city with a licensed PMA centre, keeping baseline tests and ultrasound local.
Official sources: this protocol follows ESHRE Position Paper on Uterine Fibroids and Reproduction. The DGS and CNPMA recognise these international guidelines as the basis for clinical care in Portugal.
Treatment options
Submucosal FIGO 0–2: hysteroscopic myomectomy improves pregnancy rates. Intramural with cavity distortion: laparoscopic/open myomectomy. Subserosal: generally not treated for fertility. Uterine artery embolisation (UAE) not recommended when pregnancy is desired.
Treatment choice should always weigh: female age, infertility duration, ovarian reserve (AMH), male factor, comorbidities, and patient preferences. Each option has different efficacy, risk, and cost profiles. Related treatments commonly discussed in consultation: fiv, icsi.
Plans often evolve from less to more invasive options based on response. We recommend requesting a written plan that defines the maximum number of cycles before re-evaluation, objective criteria for strategy change, and the expected impact of each decision on cumulative pregnancy probability.
Access to care in Mêda
Mêda does not currently host a CNPMA-licensed PMA centre in the municipality. The typical pathway involves: initial consultations and baseline tests (hormones, ultrasound, semen analysis) locally, with referral to the nearest authorised unit — usually Guarda. This logistics model is common in Portugal and aligned with ESHRE recommendations for decentralised access.
For SNS, referral follows the Centro ARS. Privately, clinics in Guarda may offer remote monitoring or partner with local professionals. See the clinic directory in Guarda.
Legal, ethical and psychosocial considerations
Access to infertility treatment in Portugal is regulated by Law 32/2006 (amended 2016 and 2021). Couple rights: technique-specific written informed consent, access to the medical record, second opinion, and complaint with the Health Regulator (ERS). Embryo cryopreservation is capped at 3 renewable years; gamete donation is anonymous by default (offspring may access non-identifying data at age 18).
The psychological impact of Uterine fibroids (myomas) is frequently underestimated. The Portuguese Society of Reproductive Medicine recommends structured psychological support, particularly after pregnancy loss, cycle failure, or diagnosis that changes the parental project. Many PMA units include in-house psychology; alternatively the Portuguese Order of Psychologists maintains a directory of fertility-specialised professionals.
Frequently asked questions
Is Uterine fibroids (myomas) curable?
Uterine fibroids (myomas) is a medical condition where the goal is usually symptom control and pregnancy achievement, rather than "cure" in the traditional sense. Current options enable many women to achieve motherhood — discuss your case with a reproductive medicine specialist.
Can I treat Uterine fibroids (myomas) in Mêda?
Initial evaluation can be done in Mêda, but advanced treatments (IVF, ICSI) are typically performed in Guarda or another licensed centre in the region.
How much does treatment cost?
Free at SNS for eligible patients (with waiting list). Privately, ranges €800 (IUI) to €4,000–€7,500 (IVF/ICSI). See our [pricing guide](/en/pricing) by treatment.
What is the success rate?
Depends heavily on female age, ovarian reserve, and specific cause. For IVF in Portugal, pregnancy rate per transfer is ~30–35% before age 35 and falls below 10% after age 42 (CNPMA 2023).
Is the information on this page reliable?
Yes — aligned with ESHRE Position Paper on Uterine Fibroids and Reproduction and [Law 32/2006](/en/glossary/cnpma). Reviewed by our editorial team. Contact us via [corrections](/en/corrections) if you spot an inaccuracy.
Fontes e autoridades
Conteúdo verificado com base em reguladores oficiais, sociedades científicas e legislação portuguesa.
- 1
- 2NICE Guideline CG156 — Fertility problems: assessment and treatment — National Institute for Health and Care Excellence
- 3Direção-Geral da Saúde — DGS
- 4
- 5


